Delving into the Latest Updates on Shandong Fontacea Pharmaceutical Co., Ltd with Synapse

Overview

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Immune System Diseases

Monoclonal antibody

Bispecific antibody

Antibody drug conjugate (ADC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Immune System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Bispecific antibody	3
Antibody drug conjugate (ADC)	1
Monoclonal antibody	1

Top 5 Target	Count

IL-17A(Interleukin 17A)	1
HER2 x PDL1	1
PDL1 x SIRP	1
LAG3 x PD-1	1
Trop-2(Tumor-associated calcium signal transducer 2)	1

主要研究目的：评估FTC001在健康受试者中单次皮下给药的安全性、耐受性。次要研究目的：评估FTC001在健康受试者中单次皮下给药的药代动力学和免疫原性。探索性研究目的：探索FTC001在健康受试者中单次皮下给药的药效学指标。

[Translation]

Primary study objectives: To evaluate the safety and tolerability of a single subcutaneous administration of FTC001 in healthy subjects. Secondary study objectives: To evaluate the pharmacokinetics and immunogenicity of a single subcutaneous administration of FTC001 in healthy subjects. Exploratory study objectives: To explore the pharmacodynamic indicators of a single subcutaneous administration of FTC001 in healthy subjects.

Start Date20 Jul 2023

Sponsor / Collaborator

Shandong Fontacea Pharmaceutical Co., Ltd

100 Clinical Results associated with Shandong Fontacea Pharmaceutical Co., Ltd

Login to view more data

0 Patents (Medical) associated with Shandong Fontacea Pharmaceutical Co., Ltd

Login to view more data

100 Deals associated with Shandong Fontacea Pharmaceutical Co., Ltd

Login to view more data

100 Translational Medicine associated with Shandong Fontacea Pharmaceutical Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 Jul 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

1

Phase 1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CNTO-6785 ( IL-17A )	Arthritis, Psoriatic More	Preclinical
Trop2-adc(Shandong Fontacea Pharmaceutical) ( Trop-2 )	Neoplasms More	Preclinical
HER2-PDL1 ( HER2 x PDL1 )	Neoplasms More	Preclinical
SIRPα-PDL1 ( PDL1 x SIRP )	Neoplasms More	Preclinical
LAG3-PD1 (Fontacea) ( LAG3 x PD-1 )	Neoplasms More	Preclinical